Effects of mesenchymal stem cells in renovascular hypertension

• Published in: Experimental physiology 2015-05, Vol.100 (5), p.491-495
• Main Authors: Oliveira‐Sales, Elizabeth B., Varela, Vanessa A., Bergamaschi, Cassia T., Campos, Ruy R., Boim, Mirian A.
• Format: Article
• Language: English
• Subjects: Animals; Blood Pressure - physiology; Cell- and Tissue-Based Therapy - methods; Humans; Hypertension, Renovascular - physiopathology; Hypertension, Renovascular - therapy; Kidney - metabolism; Mesenchymal Stem Cells - cytology; Renin-Angiotensin System - physiology
• ISSN: 0958-0670; 1469-445X
• DOI: 10.1113/expphysiol.2014.080531

New Findings What is the topic of this review? The major topic of this review addresses the effects of mesenchymal stem cell treatment in renovascular hypertension. What advances does it highlight? This therapy may be a promising strategy to treat renovascular hypertension and its renal consequences in the near future. Renovascular hypertension induced by the two‐kidney, one‐clip technique is a renin–angiotensin system‐dependent model that leads to renal vascular rarefaction, fibrosis and renal failure. Treatment of renovascular hypertension remains a challenge, and thus, new therapies are needed. In this report, we discuss the beneficial effects of mesenchymal stem cells on the reconstruction of the renal parenchyma of the stenotic kidney to improve vascular rarefaction and fibrosis. Mesenchymal stem cell therapy prevented the progressive increase in systolic arterial pressure, reduced sympathetic hyperactivity, improved renal morphology, induced neovascularization and reduced fibrosis in stenotic kidneys. Although this therapy may be a promising strategy to treat renovascular hypertension and its renal consequences, further studies are necessary to improve the efficiency of mesenchymal stem cells.